SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. [electronic resource]
Producer: 20180105Description: 119-132 p. digitalISSN:- 1573-7241
- AMP-Activated Protein Kinases -- metabolism
- Adamantane -- analogs & derivatives
- Animals
- Apoptosis -- drug effects
- Benzhydryl Compounds -- pharmacology
- CARD Signaling Adaptor Proteins -- antagonists & inhibitors
- Cells, Cultured
- Diabetes Mellitus, Type 2 -- complications
- Diabetic Cardiomyopathies -- enzymology
- Dipeptides -- pharmacology
- Dipeptidyl Peptidase 4 -- metabolism
- Dipeptidyl-Peptidase IV Inhibitors -- pharmacology
- Disease Models, Animal
- Drug Therapy, Combination
- Fibroblasts -- drug effects
- Fibrosis
- Glucosides -- pharmacology
- Hypoglycemic Agents -- pharmacology
- Inflammasomes -- antagonists & inhibitors
- Inflammation Mediators -- metabolism
- Kidney Tubules, Proximal -- drug effects
- Male
- Mice, Inbred C57BL
- Mice, Obese
- Myocytes, Cardiac -- drug effects
- NLR Family, Pyrin Domain-Containing 3 Protein -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Sodium-Glucose Transporter 2 -- metabolism
- Sodium-Glucose Transporter 2 Inhibitors
- Stroke Volume -- drug effects
- Time Factors
- Ventricular Function, Left -- drug effects
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.